Arzeda and TeselaGen Partner to Advance Biodesign Technologies for Industrial Biotechnology

Picture of TeselaGen Team

TeselaGen Team

Pipetting

Arzeda Corp, “The Protein Design Company™,” and TeselaGen Biotechnology Inc., a software company providing automated DNA design solutions with it’s Synthetic Evolution™ software platform, today announced that Arzeda will license TeselaGen’s proprietary cloud-based informatics solution and collaborate to extend TeselaGen’s state-of-the-art biological design automation platform.

“TeselaGen’s industry-leading software tools complement our own technology stack. With the deployment of TeselaGen’s software tools at Arzeda, we will improve our protein design pipeline throughput and implement our computationally designed enzymes and metabolic pathways more efficiently” stated Alexandre Zanghellini, Ph.D., Chief Executive Officer, Arzeda. “These tools will accelerate our design-build-test cycle, which will enable us to get products to market faster,” he continued.

Michael Fero, Ph.D., Chief Executive Officer, TeselaGen, said, “I believe that the combination of Arzeda’s advanced computational design infrastructure with the TeselaGen platform will yield one of the most advanced information technology systems for the forward engineering of microbial systems in the world.”

He continued, “TeselaGen is building a platform that automates and optimizes protocol generation and information flow for biomanufacturing. Our hypothesis is that biotechnology is essentially an information technology. Improving the flow, handling and interpretation of information is a tremendous accelerant for biotech product development.”

“TeselaGen has created a unique solution for DNA assembly design,” said George McArthur, Ph.D., Research Scientist at Arzeda. “As an Alpha Access Program member, we have already significantly improved the efficiency of our genetic design-build workflow using TeselaGen’s genetic engineering CAD software. With this collaboration, we are looking forward to scaling our workflow even further.”

Read More